Also, we observe that an anti-VEGF drug, like bevacizumab, would only contribute a ~5% decrease in VEGFR2 ligation when cross-family binding is considered in breast cancer xenograft-derived endothelial cells (Fig. 10A). Here, VEGFA is linked to breast carcinoma.